Wei Li

US Patent:

7637234, Dec 29, 2009

Filed:

Jun 11, 2008

Appl. No.:

12/157555

Inventors:

Mark Tussing - San Antonio TX, US
Wei Li - San Antonio TX, US
Gareth Roberts - New Haven, GB

Assignee:

Scuderi Group, LLC - West Springfield MA

International Classification:

F02B 33/00
F02B 31/00

US Classification:

123 70R, 123306

Abstract:

An engine has a crankshaft. A compression piston within a compression cylinder is connected to the crankshaft such that the compression piston reciprocates through an intake stroke and a compression stroke. An expansion piston within an expansion cylinder is connected to the crankshaft such that the expansion piston reciprocates through an expansion stroke and an exhaust stroke. A crossover passage interconnects the compression and expansion cylinders. The crossover passage includes a crossover compression valve and a crossover expansion valve. A runner section is in a downstream portion of the crossover passage, and a helical end section is integrally connected to the runner section. The helical end section has a funnel spiraling about a valve stem of the crossover expansion valve. The funnel forces incoming air to rotate about the valve stem prior to entering the expansion cylinder to promote turbulent kinetic energy in the cylinder air/fuel charge.

US Patent:

20050228250, Oct 13, 2005

Filed:

Nov 21, 2002

Appl. No.:

10/496435

Inventors:

Ingmar Bitter - Rockville MD, US
Wei Li - East Brunswick NJ, US
Michael Meissner - Port Jefferson NY, US
Frank Dachille - Amityville NY, US
Soren Grimm - Wurmlingen, DE
George Economos - Bayport NY, US

International Classification:

A61B005/05

US Classification:

600407000

Abstract:

A user interface () comprises an image area that is divided into a plurality of views for viewing corresponding 2-dimensional and 3-dimensional images of an anatomical region. Tool control panes (-) can be simultaneously opened and accessible. The segmentation pane () enables automatic segmentation of components of a displayed image within a user-specified intensity range or based on a predetermined intensity

US Patent:

20070179855, Aug 2, 2007

Filed:

Jan 24, 2007

Appl. No.:

11/657047

Inventors:

Ismael Enrique Arciniegas Rueda - Arlington VA, US
Anil Kumar Suri - Tarrytown NY, US
Vikram Bakshi - Westport CT, US
Glenn Bradley Christensen - New Lenox IL, US
Andrew Mark Singer - Baltimore MD, US
Gary R. Bradley - Lemont IL, US
Brian Hayduk - Tarrytown NY, US
Abhinav Krishna - Chevy Chase MD, US
Alvaro Ignacio Arciniegas Rueda - Troy NY, US
Wei Li - Parsippany NJ, US

Assignee:

Constellation Energy Group, Inc. - Baltimore MD

International Classification:

G07G 1/14

US Classification:

705 14, 705412

Abstract:

A method of determining an optimal energy portfolio for a customer includes: quantifying the customer's risk/reward profile; obtaining customer data, including historical and forward customer data, said customer data including at least customer budgetary constraints; obtaining market data, including historical and forward market data; and determining, as the optimal energy portfolio for the customer, an energy portfolio based at least in part on (i) the customer's risk/reward profile, (ii) the customer's budget constraints, (iii) the customer data; and (iv) the market data.

US Patent:

20230095075, Mar 30, 2023

Filed:

Nov 22, 2022

Appl. No.:

18/058064

Inventors:

- Bethesda MD, US
Wei LI - Potomac MD, US
Kiyoharu Joshua MIYAGISHIMA - Laurel MD, US

International Classification:

A61K 31/4985
A61K 31/336
A61K 31/34
A61K 38/08

Abstract:

A composition for preserving viability of cells, tissues, or organs at a low temperature is provided. The composition includes a mitochondrial uncoupling agent, at least one protease inhibitor, and a reducing agent. Methods to protect cells, tissues, or organs from exposure to cold and other metabolic stress are also provided.

US Patent:

20200368230, Nov 26, 2020

Filed:

Aug 20, 2018

Appl. No.:

16/636945

Inventors:

- Bethesda MD, US
Wei Li - Potomac MD, US
Kiyoharu Josh Miyagishima - Laurel MD, US

International Classification:

A61K 31/4985
A61K 31/336
A61K 38/08
A61K 31/34

Abstract:

A composition for preserving viability of cells, tissues, or organs at a low temperature is provided. The composition includes a mitochondrial uncoupling agent, at least one protease inhibitor, and a reducing agent. Methods to protect cells, tissues, or organs from exposure to cold and other metabolic stress are also provided.

US Patent:

20180099032, Apr 12, 2018

Filed:

Sep 15, 2017

Appl. No.:

15/705520

Inventors:

- Miami FL, US
Paolo Serafini - Miami FL, US
Vance Paul Lemmon - Miami FL, US
Wei Li - San Antonio TX, US
Angel Kaifer - Coral Gables FL, US
Bonnie Beth Blomberg - Coral Gables FL, US
Victor L. Perez - Miami FL, US

International Classification:

A61K 39/00
A61K 39/12
A61K 39/145
C08G 83/00

Abstract:

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle-based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE). Negatively-charged plasmids bind naturally to a positively-charged PADRE-dendrimer, while peptide or polypeptide antigens can be chemically linked to the PADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The compositions, kits, vaccines and methods described herein have both prophylactic and treatment applications, i.e., can be used as a prophylactic to prevent onset of a disease or condition in a subject, as well as to treat a subject having a disease or condition. A vaccine as described herein can be used to mount an immune response against any infectious pathogen or cancer.